Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Utah.
Press releases published on September 3, 2025
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the …
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
BURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today …
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its …
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose …
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that …
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim …
XORTX Initiates IND Preparation for XORLO™ in Gout Program
CALGARY, Alberta, Sept. 03, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride
Breakthrough findings open doors to multi-billion-dollar infection-control markets SALT LAKE CITY, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in …
Aclarion Appoints Greg Gould as Chief Financial Officer
HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening …
WeightWatchers Advances International Growth With Strategic Leadership Appointment
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the appointment of Alejandro Bethlen as Executive Vice President, …
WeightWatchers treibt internationales Wachstum mit strategischer Verstärkung im Führungsteam voran
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) („WeightWatchers“ oder das „Unternehmen“), der weltweit führende, wissenschaftlich fundierte Experte für Gewichtsmanagement i, gab heute bekannt, dass Alejandro Bethlen mit …
Fangzhou Secures 2nd National Science Foundation Project Approval, Deepens AI-Driven Healthcare Research
SHANGHAI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its technology team will collaborate on a National Natural Science Foundation of China …
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that Gordon Ringold, PhD has …
Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models
Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models Guiding biotech teams from scientific breakthroughs to commercial inflection with investor-grade strategy and execution Chicago, IL …
Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment
Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciences Allegro prepares to advance lead product hydrocelin into clinical trials in 2026 Liege, …
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with …
Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme
Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappel Forte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le comité …
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and commercialization in the US and …
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected
LOS ANGELES and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today provided an update regarding …
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), …